BioSpace News Archive

Business

AbbVie-Backed Disco Launches with $20M in Funding, Targets Oncology

Disco Pharmaceuticals is taking to the biotech dance floor with seed funding from major players and pipeline programs in small cell lung cancer and colorectal cancer.

January 16, 2024
·
2 min read
·
Tyler Patchen
Business

Allakos Axes Half of Its Workforce, Drops Lead Inflammatory Candidate

The biotech Tuesday announced a restructuring plan as its humanized IgG1 antibody lirentelimab failed two Phase II studies in atopic dermatitis and chronic spontaneous urticaria.

January 16, 2024
·
2 min read
·
Tristan Manalac
Could Treatments for HIV and Sickle Cell Open the Gene Therapy Floodgates?

The Gates Foundation and some biotechs are betting that the technology could be deployed at scale.

January 16, 2024
·
5 min read
·
Shawna Williams
Business

Pan Orion Invests $415M in Korean Biotech LegoChem, Secures Majority Stake

The snacks and confectionery giant has been seeking to enter the biopharmaceuticals space in recent years.

January 16, 2024
·
2 min read
·
Tristan Manalac
FDA

FDA Approves Vertex, CRISPR’s Casgevy to Treat Beta Thalassemia

Vertex Pharmaceuticals and CRISPR Therapeutics have secured another FDA approval for their Casgevy Cas9 gene-edited cell therapy, this time in treating transfusion-dependent beta thalassemia.

January 16, 2024
·
2 min read
·
Tyler Patchen
Despite Tough Market, Some Life Science IPOs Find Success

The handful of biotechs that went public in 2023 fared well, providing hope to a cautiously optimistic sector.

January 16, 2024
·
4 min read
·
Mollie Barnes
Deals

Alto, Kyverna Join Growing Number of Biotech IPO Filings in 2024

Alto Neuroscience and Kyverna Therapeutics are following in the footsteps of CG Oncology, Metagenomi and Arrivent in seeking initial public offerings this year.

January 16, 2024
·
2 min read
·
Tristan Manalac
International Diabetes Federation and Sanofi Global Health Unit collaborate to strengthen diabetes response in 40 countries

The International Diabetes Federation, in collaboration with Sanofi’s Global Health Unit, is taking significant steps to improve access to diabetes care.

January 16, 2024
·
3 min read
Hemogenyx Pharmaceuticals PLC Announces Submission of Complete Response to Clinical Hold

Hemogenyx Pharmaceuticals plc announces the submission of a complete response tothe previously announced Clinical Hold of the Investigational New Drug application to the US Food and Drug Administration for HEMO-CAR-T.

January 16, 2024
·
2 min read
Drug Development

Chipscreen NewWay: First Patient Dosed in Phase 1 Trial of the Bispecific Antibody NWY001, a Next-generation Tumor Immunotherapy in Patients with Advanced Solid Tumors

Chengdu Chipscreen NewWay Biosciences Co., Ltd. announced that on January 5, 2024, the dosing of the first patient for a phase I clinical trial of a PD-1/CD40 bispecific antibody, NWY001, at Sun Yat-Sen University Cancer Center in China, the trial-leading institution.

January 16, 2024
·
5 min read